 Proto-Oncogene Proteins c-abl
"Proto-Oncogene Proteins c-abl" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Non-receptor tyrosine kinases encoded by the C-ABL GENES. They are distributed in both the cytoplasm and the nucleus. c-Abl plays a role in normal HEMATOPOIESIS especially of the myeloid lineage. Oncogenic transformation of c-abl arises when specific N-terminal amino acids are deleted, releasing the kinase from negative regulation.
| Descriptor ID |
D016315
|
| MeSH Number(s) |
D08.811.913.696.620.682.725.500 D12.776.624.664.700.167
|
| Concept/Terms |
Proto-Oncogene Proteins c-abl- Proto-Oncogene Proteins c-abl
- Proto Oncogene Proteins c abl
- c-abl, Proto-Oncogene Proteins
- Proto-Oncogene Proteins abl
- Proteins abl, Proto-Oncogene
- Proto Oncogene Proteins abl
- abl, Proto-Oncogene Proteins
- c-abl Proteins
- c abl Proteins
- abl Proto-Oncogene Products
- Products, abl Proto-Oncogene
- Proto-Oncogene Products, abl
- abl Proto Oncogene Products
- abl Proto-Oncogene Proteins
- Proto-Oncogene Proteins, abl
- abl Proto Oncogene Proteins
|
Below are MeSH descriptors whose meaning is more general than "Proto-Oncogene Proteins c-abl".
Below are MeSH descriptors whose meaning is more specific than "Proto-Oncogene Proteins c-abl".
This graph shows the total number of publications written about "Proto-Oncogene Proteins c-abl" by people in this website by year, and whether "Proto-Oncogene Proteins c-abl" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 | | 1996 | 4 | 0 | 4 | | 1997 | 4 | 0 | 4 | | 1998 | 4 | 0 | 4 | | 1999 | 1 | 0 | 1 | | 2000 | 3 | 0 | 3 | | 2001 | 1 | 0 | 1 | | 2005 | 1 | 1 | 2 | | 2010 | 1 | 0 | 1 | | 2014 | 0 | 1 | 1 | | 2015 | 3 | 0 | 3 | | 2016 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Proto-Oncogene Proteins c-abl" by people in Profiles.
-
DeBoer R, Koval G, Mulkey F, Wetzler M, Devine S, Marcucci G, Stone RM, Larson RA, Bloomfield CD, Geyer S, Mullighan CG, Stock W. Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665. Leuk Lymphoma. 2016 10; 57(10):2298-306.
-
Dunn DM, Woodford MR, Truman AW, Jensen SM, Schulman J, Caza T, Remillard TC, Loiselle D, Wolfgeher D, Blagg BS, Franco L, Haystead TA, Daturpalli S, Mayer MP, Trepel JB, Morgan RM, Prodromou C, Kron SJ, Panaretou B, Stetler-Stevenson WG, Landas SK, Neckers L, Bratslavsky G, Bourboulia D, Mollapour M. c-Abl Mediated Tyrosine Phosphorylation of Aha1 Activates Its Co-chaperone Function in Cancer Cells. Cell Rep. 2015 Aug 11; 12(6):1006-18.
-
Shao L, Miller S, Keller-Ramey J, Zhang Y, Roulston D. Cytogenetic, fluorescence in situ hybridization, and genomic array characterization of chronic myeloid leukemia with cryptic BCR-ABL1 fusions. Cancer Genet. 2015 Jul-Aug; 208(7-8):396-403.
-
Martin E, Knapp S, Engh RA, Moebitz H, Varin T, Roux B, Meiler J, Berdini V, Baumann A, Vieth M. Perspective on computational and structural aspects of kinase discovery from IPK2014. Biochim Biophys Acta. 2015 Oct; 1854(10 Pt B):1595-604.
-
Fu P, Usatyuk PV, Lele A, Harijith A, Gregorio CC, Garcia JG, Salgia R, Natarajan V. c-Abl mediated tyrosine phosphorylation of paxillin regulates LPS-induced endothelial dysfunction and lung injury. Am J Physiol Lung Cell Mol Physiol. 2015 May 15; 308(10):L1025-38.
-
Meng Y, Lin YL, Roux B. Computational study of the "DFG-flip" conformational transition in c-Abl and c-Src tyrosine kinases. J Phys Chem B. 2015 Jan 29; 119(4):1443-56.
-
Lin YL, Meng Y, Huang L, Roux B. Computational study of Gleevec and G6G reveals molecular determinants of kinase inhibitor selectivity. J Am Chem Soc. 2014 Oct 22; 136(42):14753-62.
-
Israyelyan A, Goldstein L, Tsai W, Aquino L, Forman SJ, Nakamura R, Diamond DJ. Real-time assessment of relapse risk based on the WT1 marker in acute leukemia and myelodysplastic syndrome patients after hematopoietic cell transplantation. Bone Marrow Transplant. 2015 Jan; 50(1):26-33.
-
Lin YL, Meng Y, Jiang W, Roux B. Explaining why Gleevec is a specific and potent inhibitor of Abl kinase. Proc Natl Acad Sci U S A. 2013 Jan 29; 110(5):1664-9.
-
Dudek SM, Chiang ET, Camp SM, Guo Y, Zhao J, Brown ME, Singleton PA, Wang L, Desai A, Arce FT, Lal R, Van Eyk JE, Imam SZ, Garcia JG. Abl tyrosine kinase phosphorylates nonmuscle Myosin light chain kinase to regulate endothelial barrier function. Mol Biol Cell. 2010 Nov 15; 21(22):4042-56.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|